Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 June 2020Website:
http://generationbio.comNext earnings report:
06 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:02:46 GMTDividend
Analysts recommendations
Institutional Ownership
GBIO Latest News
CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress.
GBIO reported a quarterly loss of $1.12 per share, which was higher than the Zacks Consensus Estimate of a loss of $0.36. This is an increase from the loss of $0.53 per share reported in the same quarter last year.
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.55 per share a year ago.
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2024 TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 9:10 a.m. ET in Boston.
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.61 per share a year ago.
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023 at 1:00 p.m. EST in New York.
What type of business is Generation Bio Co?
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
What sector is Generation Bio Co in?
Generation Bio Co is in the Healthcare sector
What industry is Generation Bio Co in?
Generation Bio Co is in the Biotechnology industry
What country is Generation Bio Co from?
Generation Bio Co is headquartered in United States
When did Generation Bio Co go public?
Generation Bio Co initial public offering (IPO) was on 12 June 2020
What is Generation Bio Co website?
https://generationbio.com
Is Generation Bio Co in the S&P 500?
No, Generation Bio Co is not included in the S&P 500 index
Is Generation Bio Co in the NASDAQ 100?
No, Generation Bio Co is not included in the NASDAQ 100 index
Is Generation Bio Co in the Dow Jones?
No, Generation Bio Co is not included in the Dow Jones index
When was Generation Bio Co the previous earnings report?
No data
When does Generation Bio Co earnings report?
The next expected earnings date for Generation Bio Co is 06 March 2025